Current Status of Multi Drug Resistance- Tuberculosis: A Major Public-Health Threat

Abstract

Background: Rifampicin is the most effective first-line antibiotic for tuberculosis (TB). However, drug resistance, particularly multidrug-resistant TB (MDR-TB), poses a significant global health challenge. According to the World Health Organization (WHO), approximately 500,000 new TB cases in 2019 were resistant to treatment, with 78% showing multidrug resistance. India alone accounted for 27% of all MDR or rifampicin-resistant (RR) TB cases reported in 2020. MDR-TB, defined by resistance to at least isoniazid and rifampicin, is primarily driven by poor adherence to treatment, inappropriate antibiotic use, and transmission in crowded settings.

Purpose: This review highlights the increasing threat of MDR-TB and underscores the need for alternative therapeutic strategies, improved diagnostic tools, and updated treatment guidelines to combat drug-resistant TB effectively.

Methods: A literature-based analysis was conducted, focusing on recent WHO reports, updated guidelines, and emerging approaches in MDR-TB diagnosis and management, including molecular diagnostics, novel oral drugs, and adjunctive therapies such as nutritional and traditional support systems.

Results: Recent WHO guidelines emphasize early detection using advanced molecular techniques and the use of repurposed oral anti-TB medications. These strategies show promise in enhancing disease control and patient outcomes. However, the implementation of new regimens requires further clinical evaluation. Integration of supportive care approaches such as nutrition and traditional therapies may contribute to a more holistic management of MDR-TB.

Conclusion: The growing prevalence of MDR-TB and XDR-TB calls for urgent action in diagnosis, treatment, and patient support. While revised WHO strategies offer a promising framework, continued research and clinical trials are vital to optimize therapies and address global TB drug resistance effectively.

  • Page Number : 83-97
  • Published Date : 2024-11-20
  • Keywords
    Epidemiological burden, MDR-TB, Transmission, Alternative therapies, Molecular testing
  • DOI Number
    10.15415/jptrm.2024.122007
  • Authors
    Deepak Kajla, Veerta Sharma, Ashi Mannan, Tanveer singh, and Pankaj Kumar Singh

References

  • Ahmed, H. M. (2016). Ethnopharmacobotanical study on the medicinal plants used by herbalists in Sulaymaniyah Province, Kurdistan, Iraq. Journal of Ethnobiology and Ethnomedicine, 12, 8.
  • Ahuja, S. D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J. N., et al. (2012). Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients. PLoS Medicine, 9(e1001300). https://doi.org/10.1371/journal.pmed.1001300
  • Aibana, O., Huang, C.-C., Aboud, S., et al. (2019). Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis. PLoS Medicine, 16, e1002907.
  • Aranow, C. (2011). Vitamin D and the immune system. Journal of Investigative Medicine, 59, 881–886.
  • Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E. M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E. H., Rollinger, J. M., Schuster, D., Breuss, J. M., Bochkov, V., Mihovilovic, M. D., Kopp, B., Bauer, R., Dirsch, V. M., & Stuppner, H. (2015). Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnology Advances, 33(8), 1582–1614.
  • Barnard, M., Gey van Pittius, N. C., van Helden, P. D., Bosman, M., Coetzee, G., & Warren, R. M. (2012). The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. Journal of Clinical Microbiology, 50(12), 3712–3716. https://doi.org/10.1128/JCM.01958-12
  • Bellamy, R., Ruwende, C., & Corrah, T. (1999). Tuberculosis and hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. Journal of Infectious Diseases, 179, 721–724.
  • Brown, E. D., Chan, W., & Smith, J. C. Jr. (1976). Vitamin A metabolism during the repletion of zinc-deficient rats. Journal of Nutrition, 106, 563–568.
  • Camacho‐Corona, M. R., Ramírez‐Cabrera, M. A., Santiago, O. G., Garza‐González, E., Palacios, I. P., & Luna‐Herrera, J. (2008). Activity against drug-resistant tuberculosis strains of plants used in Mexican traditional medicine to treat tuberculosis and other respiratory diseases. Phytotherapy Research, 22(1), 82–85.
  • Caminero, J. A. (2008). Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. International Journal of Tuberculosis and Lung Disease, 12, 869–877.
  • Caminero, J. A. (2010). Multidrug-resistant tuberculosis: Epidemiology, risk factors and case finding. International Journal of Tuberculosis and Lung Disease, 14, 382–390.
  • Centers for Disease Control and Prevention (CDC). (2013). Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recommendations and Reports, 62, 1–12.
  • Centers for Disease Control and Prevention. (2020). Tuberculosis (TB) disease: Symptoms and risk factors. Retrieved December 29, 2020, from https://www.cdc.gov/tb/topic/basics/default.htm
  • Chand, K. S., Manchanda, R. K., Mittal, R., et al. (2014). Homeopathic treatment in addition to standard care in multidrug-resistant pulmonary tuberculosis: A randomized, double-blind, placebo-controlled clinical trial. Homeopathy, 103(2), 97–107. https://doi.org/10.1016/j.homp.2014.02.001
  • Choi, H. W., Miele, K., Dowdy, D., & Shah, M. (2013). Cost-effectiveness of Xpert MTB/RIF for diagnosing pulmonary tuberculosis in the United States. International Journal of Tuberculosis and Lung Disease, 17(10), 1328–1335.
  • Corbett, E. L., Marston, B., Churchyard, G. J., & De Cock, K. M. (2006). Tuberculosis in sub-Saharan Africa: Opportunities, challenges, and change in the era of antiretroviral treatment. The Lancet, 367(9514), 926–937.
  • Coussens, A. K., Martineau, A. R., & Wilkinson, R. J. (2014). Anti-inflammatory and antimicrobial actions of vitamin D in combating TB/HIV. Scientifica, 2014, 1–13.
  • Coussens, A. K., Wilkinson, R. J., Hanifa, Y., et al. (2012). Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proceedings of the National Academy of Sciences of the United States of America, 109(38), 15449–15454.
  • Cox, H. S., McDermid, C., Azevedo, V., Muller, O., Coetzee, D., Simpson, J., Barnard, M., Coetzee, G., van Cutsem, G., & Goemaere, E. (2010). Epidemic levels of drug-resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS One, 5, e13901.
  • Cragg, G. M., & Newman, D. J. (2013). Natural products: A continuing source of novel drug leads. Biochimica et Biophysica Acta, 1830(6), 3670–3695.
  • Crowle, A. J., & Ross, E. J. (1989). Inhibition of retinal acid of multiplication on virulent tubercle bacilli in cultured human macrophages. Infection and Immunity, 57, 840–844.
  • Davis, L., & Kuttan, G. (2002). Effect of Withania somnifera on cell mediated immune responses in mice. Journal of Experimental & Clinical Cancer Research, 21, 585–590.
  • De Rossi, E., Aínsa, J. A., & Riccardi, G. (2006). Role of mycobacterial efflux transporters in drug resistance: An unresolved question. FEMS Microbiology Reviews, 30, 36–52.
  • Debnath, P. K., Chattopadhyay, J., Ghosal, D., et al. (2012). Immunomodulatory role of Ayurvedic Rasayan for quality of life. International Natural Conference, 3(3), 141–149.
  • Debnath, P. K., Chattopadhyay, J., Mitra, A., Adhikari, A., Alam, M. S., Bandopadhyay, S. K., & Hazra, J. (2012). Adjunct therapy of Ayurvedic medicine with anti-tubercular drugs on the therapeutic management of pulmonary tuberculosis. Journal of Ayurveda and Integrative Medicine, 3(3), 141–149. https://doi.org/10.4103/0975-9476.100168
  • Faustini, A., Hall, A. J., & Perucci, C. A. (2006). Risk factors for multidrug-resistant tuberculosis in Europe: A systematic review. Thorax, 61, 158–163.
  • FIND. (2013). Price for Xpert® MTB/RIF and FIND country list. Retrieved from www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/xpert_mtb_rif.html
  • Fox, G. J., Barry, S. E., Britton, W. J., & Marks, G. B. (2013). Contact investigation for tuberculosis: A systematic review and meta-analysis. European Respiratory Journal, 41, 140–156.
  • Frieden, T. R., Fujiwara, P. I., Washko, I. M., & Hamburg, M. A. (1995). Tuberculosis in New York City: Turning the tide. New England Journal of Medicine, 333, 229–233.
  • Furin, J., Bayona, J., Becerra, M., Farmer, P., Golubkov, A., Hurtado, R., et al. (2011). Programmatic management of multidrug-resistant tuberculosis: Models from three countries. International Journal of Tuberculosis and Lung Disease, 15, 1294–1300.
  • Ganmaa, D., Munkhzul, B., Fawzi, W., et al. (2017). High-dose vitamin D3 during tuberculosis treatment in Mongolia: A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine, 196, 628–637.
  • Gautam, H. A., Sharma, R., & Rana, A. C. (2012). Review on herbal plants useful in tuberculosis. International Research Journal of Pharmacy, 3(7), 64–67.
  • Gautam, R., Saklani, A., & Jachak, S. M. (2007). Indian medicinal plants as a source of antimycobacterial agents. Journal of Ethnopharmacology, 110(2), 200–234. https://doi.org/10.1016/j.jep.2006.11.034
  • Gopalan, C. (1957). Importance of nutritional factors in tuberculosis. Indian Journal of Tuberculosis, 4(3), 105–112.
  • Hannan, A., Ikram Ullah, M., Usman, M., Hussain, S., Absar, M., & Javed, K. (2011). Anti-mycobacterial activity of garlic (Allium sativum) against multi-drug resistant and non-multi-drug resistant Mycobacterium tuberculosis. Pakistan Journal of Pharmaceutical Sciences, 24(1), 81–85.
  • Hillemann, D., Rusch-Gerdes, S., & Richter, E. (2007). Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. Journal of Clinical Microbiology, 45, 2635–2640.
  • Huang, S.-J., Wang, X.-H., Liu, Z.-D., et al. (2017). Vitamin D deficiency and the risk of tuberculosis: A meta-analysis. Drug Design, Development and Therapy, 11, 91–102.
  • Jamil, S., Azhar, J., & Ahmed, S. (2005). Pulmonary tuberculosis and its management in classical Unani literature. Indian Journal of Traditional Knowledge, 4(2), 143–149.
  • Jindani, A., Aber, V. R., Edwards, E. A., & Mitchison, D. A. (1980). The early bactericidal activity of drugs in patients with pulmonary tuberculosis. American Review of Respiratory Disease, 121, 939–949.
  • Jolliffe, D. A., Ganmaa, D., Wejse, C., et al. (2019). Adjunctive vitamin D in tuberculosis treatment: Meta-analysis of individual participant data. European Respiratory Journal, 53. https://doi.org/10.1183/13993003.02003-2018
  • Karyadi, E., Schultink, W., Nelwan, R. H., Gross, R., Amin, Z., Dolmans, W. M., et al. (2000). Poor micronutrient status of active pulmonary tuberculosis in Indonesia. Journal of Nutrition, 130, 2953–2958.
  • Karyadi, E., West, C. E., Schultink, W., Nelwan, R. H., Gross, R., Amin, Z., et al. (2002). A double blind, placebo controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: Effects on clinical response and nutritional status. American Journal of Clinical Nutrition, 75(4), 720–727.
  • Kinghorn, A. D., Pan, L., Fletcher, J. N., & Chai, H. (2011). The relevance of higher plants in lead compound discovery programs. Journal of Natural Products, 74(6), 1539–1555.
  • Kitab, R. J. (1991). Al-Havi (Urdu Translation). Central Council of Research in Unani Medicine.
  • Krishna Bihari Gupta. (2009). Lung India, 26(1), 9–16.
  • Larcombe, L., Orr, P., Turner-Brannen, E., et al. (2012). Effect of vitamin D supplementation on Mycobacterium tuberculosis-induced innate immune responses in a Canadian Dené first nations cohort. PLoS One, 7, e40692.
  • Lawn, S. D., Obeng, J., Acheampong, J. W., & Griffin, G. E. (2000). Resolution of acute phase response in West African patients receiving treatment for pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease, 4(4), 340–344.
  • Li, X.-Z., & Nikaido, H. (2009). Efflux-mediated drug resistance in bacteria: An update. Drugs, 69, 1555–1623.
  • LoBue, P. (2009). Extensively drug-resistant tuberculosis. Current Opinion in Infectious Diseases, 22, 167–173.
  • Lonnroth, K., Williams, B. G., Stadlin, S., Jaramillo, E., & Dye, C. (2008). Alcohol use as a risk factor for tuberculosis: A systematic review. BMC Public Health, 8, 289.
  • Madebo, T., Lindtjørn, B., Aukrust, P., & Berge, R. K. (2003). Circulating antioxidants and lipid peroxidation products in untreated tuberculosis patients in Ethiopia. American Journal of Clinical Nutrition, 78(1), 117–122.
  • Magee, M. J., Sun, Y. V., Brust, J. C. M., et al. (2017). Polymorphisms in the vitamin D receptor gene are associated with reduced rate of sputum culture conversion in multidrug-resistant tuberculosis patients in South Africa. PLoS ONE, 12, e0180916.
  • Martin, A., Panaiotov, S., Portaels, F., Hoffner, S., Palomino, J. C., & Angeby, K. (2008). The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 62, 56–64.
  • Martineau, A. R., Wilkinson, R. J., Wilkinson, K. A., et al. (2007). A single dose of vitamin D enhances immunity to mycobacteria. American Journal of Respiratory and Critical Care Medicine, 176(2), 208–213.
  • Mayatepek, E., Paul, K., Leichsenring, M., Pfisterer, M., Wagner, D., Domann, M., et al. (1994). Influence of dietary (n-3) polyunsaturated fatty acids on leukotriene B4 and prostaglandin E2 synthesis and course of experimental tuberculosis in guinea pigs. Infection, 22(2), 106–112.
  • Millard, J. (2015, February 26). Clinical lecturer in global health. BMJ, 350, h882. https://doi.org/10.1136/bmj.h882
  • Mitchison, D. A. (1998). How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. International Journal of Tuberculosis and Lung Disease, 2, 10–15.
  • Mitnick, C., Bayona, J., Palacios, E., Shin, S., Furin, J., Alcántara, F., et al. (2003). Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. New England Journal of Medicine, 348(2), 119–128. https://doi.org/10.1056/NEJMoa022186
  • Moore, D. A., Evans, C. A., Gilman, R. H., Caviedes, L., Coronel, J., & Vivar, A. (2006). Microscopic-observation drug-susceptibility assay for the diagnosis of TB. New England Journal of Medicine, 355, 1539–1550.
  • Mubarak, H. (2012). Siddha marine drug Palagarai: A review. Indian Journal of Geo-Marine Science, 41, 121–123.
  • Mukherjee, J. S. (2004, February 7). [Review of the book]. The Lancet, 363. Retrieved from www.thelancet.com
  • Newman, D. J., & Cragg, G. M. (2007). Natural products as sources of new drugs over the last 25 years. Journal of Natural Products, 70(3), 461–477.
  • News-medical.net. (2010). History of Tuberculosis. Retrieved October 15, 2010, from http://www.news-medical.net/health/History-of-Tuberculosis.aspx
  • Nguyen, L., & Thompson, C. J. (2006). Foundations of antibiotic resistance in bacterial physiology: The mycobacterial paradigm. Trends in Microbiology, 14, 304–312.
  • Nobelprize.org. (2010). The Nobel Prize in Physiology or Medicine: 1905 Robert Koch. Retrieved October 15, 2010, from http://nobelprize.org/nobel_prizes/medicine/laureates/1905/koch.html
  • Pablos-Mendez, A., Raviglione, M. C., Laszlo, A., et al. (1998). Global surveillance for antituberculosis-drug resistance, 1994–1997: World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. New England Journal of Medicine, 338, 1641–1649.
  • Panasiuk, A. V., Penenko, O. R., Kuz'menko, I. V., Suslov, E. I., Klimenko, M. T., Kuznitsa, N. I., et al. (1991). Vitamin E and its structural analogs in tuberculosis. Ukrainskii Biokhimicheskii Zhurnal, 63, 83–88.
  • Pervez-Guzman, C., Vargas, M. H., Quinonez, F., Bazavilvazo, N., & Aguilar, A. (2005). A cholesterol rich diet accelerates bacteriological sterilization in pulmonary tuberculosis. Chest, 127(2), 643–651.
  • Peter, J. G., Theron, G., Pooran, A., Thomas, J., Pascoe, M., & Dheda, K. (2013). Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: A randomised controlled trial. Lancet Respiratory Medicine, 1, 471–478.
  • Pinto, L., & Menzies, D. (2011). Treatment of drug-resistant tuberculosis. Infection and Drug Resistance, 4, 129–135.
  • Priyanka Sharma, Sharma, P., et al. (n.d.). TB diagnosis in traditional medicine. Drug Research.
  • Rafiei, N., Williams, J., Mulley, W. R., Trauer, J. M., Jenkin, G. A., & Rogers, B. A. (2019). Mycobacterium tuberculosis: Active disease and latent infection in a renal transplant cohort. Nephrology, 24, 569–574.
  • Raizada, N., Sachdeva, K. S., Chauhan, D. S., Malhotra, B., Reddy, K., Dave, P. V., et al. (2014). A multi-site validation in India of the line probe assay for the rapid diagnosis of multi-drug resistant tuberculosis directly from sputum specimens. PLoS One, 9, e88626.
  • Razi, Z. (1991). Kitabul-Mansoori (Urdu Translation). Central Council of Research in Unani Medicine.
  • Roth, D. E., Soto, G., Arenas, F., et al. (2004). Association between vitamin D receptor gene polymorphisms and response to treatment of pulmonary tuberculosis. Journal of Infectious Diseases, 190, 920–927.
  • Rubin, S. A. (1995). Tuberculosis: Captain of all these men of death. Radiologic Clinics of North America, 33, 619–639.
  • Rwangabwoba, J. M., Fischman, H., & Semba, R. D. (1998). Serum vitamin A levels during tuberculosis and human immunodeficiency virus infection. International Journal of Tuberculosis and Lung Disease, 2(9), 771–773.
  • Sailaja, C. (2000). A few research outcomes relevant for public health from Indian system of medicine. Journal of Health & Population in Developing Countries, 3, 109.
  • Samad, A., Sultana, Y., Akhter, M. S., & Aqil, M. (2008). Treatment of tuberculosis: Use of active pharmaceuticals. Recent Patents on Anti-Infective Drug Discovery, 3, 34–44.
  • Samal, J. (2016). Ayurvedic management of pulmonary tuberculosis: A systematic review. Journal of Intercultural Ethnopharmacology, 5(1), 86–91. https://doi.org/10.5455/jice.20160115121226
  • Semba, R. D. (1998). The role of vitamin A and related retinoids in immune function. Nutrition Reviews, 56, S38–S48.
  • Seung, K. J., Kwonjune, J., et al. (2015). Cold Spring Harbor Perspectives in Medicine, 5, a017863.
  • Shankar, A. H., & Prasad, A. S. (1998). Zinc and immune function: The biological basis of altered resistance to infection. American Journal of Clinical Nutrition, 68, 447S–463S.
  • Sharifi-Rad, J., Sharifi-Rad, J., et al. (2020). Biotechnology Advances, 44, 107629.
  • Sharma, A. (2021). J. Med. Chem., 64, 4359–4395.
  • Sharma, J. B., Sharma, E., Sharma, S., & Dharmendra, S. (2018). Female genital tuberculosis: Revisited. Indian Journal of Medical Research, 148(Suppl.), S71–S83.
  • Sharma, S. K., Mohan, A., & Sharma, A. (2016). Miliary tuberculosis: A new look at an old foe. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 3, 13–27.
  • Shin, S., Pasechnikov, A. D., Gelmanova, I. Y., Peremitin, G. G., Strelis, A. K., Mishustin, S., et al. (2006). Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. International Journal of Tuberculosis and Lung Disease, 10(4), 402–408.
  • Skrahina, A., Hurevich, H., Zalutskaya, A., Sahalchyk, E., Astrauko, A., van Gemert, W., Hoffner, S., Rusovich, V., & Zignol, M. (2012). Alarming levels of drug-resistant tuberculosis in Belarus: Results of a survey in Minsk. European Respiratory Journal, 39, 1425–1431.
  • Smith, I. (2003). Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clinical Microbiology Reviews, 16, 463–496.
  • Smith, M. J., & Logan, A. C. (2002). Naturopathy. Medical Clinics of North America, 86(1), 173–184. https://doi.org/10.1016/S0025-7125(03)00077-5
  • Suvetha, C., Vanitha, A., Pushparani, R. M., et al. (2016). Anti-tuberculosis activity of a Siddha herbal formulation for treating tuberculosis in children. International Journal of Advanced Research in Biological Sciences, 3(4), 173–177.
  • Syed, K., Roy, C. R., & Muchatar, R. U. (Eds.). (2002). Traditional medicine in Asia. WHO-Regional Office for South-East Asia.
  • Tabuti, J. R. S., Kukunda, C. B., & Waako, P. J. (2010). Medicinal plants used by traditional medicine practitioners in the treatment of tuberculosis and related ailments in Uganda. Journal of Ethnopharmacology, 127(1), 130–136. https://doi.org/10.1016/j.jep.2009.09.035
  • Talbot, E. A., & Raffa, B. J. (2015). Mycobacterium tuberculosis. In Y.-W. Tang, M. Sussman, D. Liu, I. Poxton, & J. Schwartzman (Eds.), Molecular Medical Microbiology (2nd ed., Vol. 3, pp. 1637–1653). Academic Press.
  • Taylor, C. G., & Bray, T. M. (1991). Effect of hyperoxia on oxygen free radical defence enzymes in the lung of zinc-deficient rats. Journal of Nutrition, 121, 460–466.
  • Torrelles, J. B., & Schlesinger, L. S. (2017). Integrating lung physiology, immunology, and tuberculosis. Trends in Microbiology, 25, 688–697.
  • Torres-Gonzalez, P., Soberanis-Ramos, O., Martinez-Gamboa, A., Chavez-Mazari, B., Barrios-Herrera, M. T., Torres-Rojas, M., Cruz-Hervert, L. P., Garcia-Garcia, L., Singh, M., Gonzalez-Aguirre, A., Ponce de Leon-Garduno, A., Sifuentes-Osornio, J., & Bobadilla-DelValle, M. (2013). Prevalence of latent and active tuberculosis among dairy farm workers exposed to cattle infected by Mycobacterium bovis. PLoS Neglected Tropical Diseases, 7, e2177.
  • Tukvadze, N., Sanikidze, E., Kipiani, M., et al. (2015). High-dose vitamin D3 in adults with pulmonary tuberculosis: A double-blind randomized controlled trial. American Journal of Clinical Nutrition, 102, 1059–1069.
  • Van Deun, A., Maug, A. K., Salim, M. A., Das, P. K., Sarker, M. R., Daru, P., et al. (2010). Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine, 182(5), 684–692. https://doi.org/10.1164/rccm.201001-0077OC
  • Volosevich, G. V. (1982). Functional activity of blood T-lymphocytes in patients with pulmonary tuberculosis treated with chemotherapeutic drugs and vitamins. Problemy Tuberkuleza, 3, 47–50.
  • Wells, C. D., Cegielski, J. P., Nelson, L. J., Laserson, K. F., Holtz, T. H., Finlay, A., Castro, K. G., & Weyer, K. (2007). HIV infection and multidrug-resistant tuberculosis: The perfect storm. Journal of Infectious Diseases, 196, S86–S107.
  • World Health Organization. (2000). Anti-tuberculosis drug resistance in the world, report no. 2: prevalence and trends. Publication WHO/CDS/TB/2000.278. Geneva: World Health Organization.
  • World Health Organization. (2009). Global tuberculosis report. Geneva: WHO.
  • World Health Organization. (2011). Guidelines for the programmatic management of drug-resistant tuberculosis. https://apps.who.int/iris/handle/10665/44597
  • World Health Organization. (2011). Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis: Policy statement. WHO.
  • World Health Organization. (2013). Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. WHO.
  • World Health Organization. (2013). The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy guidance. World Health Organization.
  • World Health Organization. (2014). Global tuberculosis report 2014. WHO.
  • World Health Organization. (2015). Global tuberculosis report. WHO.
  • World Health Organization. (2020). Global tuberculosis report 2020. Geneva: World Health Organization. Retrieved December 29, 2020, from https://www.who.int/publications/i/item/9789240013131
  • Xia, J., Shi, L., Zhao, L., et al. (2014). Impact of vitamin D supplementation on the outcome of tuberculosis treatment: A systematic review and meta-analysis of randomized controlled trials. Chinese Medical Journal, 127, 3127–3134.
  • Zeng, J., Wu, G., Yang, W., et al. (2015). A serum vitamin D level. PLoS One, 10, e0126014.
  • Zetola, N. M., Shin, S. S., Tumedi, K. A., Moeti, K., Ncube, R., Nicol, M., et al. (2014). Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. Journal of Clinical Microbiology, 52, 2422–2429.
  • Zhao, Y., Xu, S., Wang, L., Chin, D. P., Wang, S., Jiang, G., Xia, H., Zhou, Y., Li, Q., Ou, X., et al. (2012). National survey of drug-resistant tuberculosis in China. New England Journal of Medicine, 366, 2161–2170.